Amyloid β-Protein (25-35) amide
目录号 : GA20745
Amyloid β-Protein (25-35) amide是β淀粉样蛋白(amyloid-β,Aβ)酰胺化的一种产物,其中β淀粉样蛋白的生成能力已被强烈降低。
Cas No.:147490-49-1
Sample solution is provided at 25 µL, 10mM.
Amyloid β-Protein (25-35) amide is a product of the amidation of amyloid-β (Aβ), in which the ability to generate Aβ is strongly reduced[1]. Amyloid β-Protein (25-35) amide is a modified fragment sequence of the Aβ peptide, consisting of amino acids 25-35, with the C-terminus blocked by an amide bond[2]. The amino acid sequence of Aβ (25-35) peptide is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents amino acid 25 and the last Met represents amino acid 35[3]. Aβ is neurotoxic, but the strength of the toxicity is not related to its aggregation state. Aβ oligomers also show neurotoxicity and cause neuronal damage[4, 5]. Aβ is involved in the pathogenesis of Alzheimer's disease and is present in neurons of the subiculum and entorhinal cortex of Alzheimer's brain samples and inclusion body myositis (IBM) muscles. It binds to receptors present in microglia and is able to insert into lipid membranes[6].
References:
[1] Li H, Rahimi F, Bitan G. Modulation of amyloid β-protein (Aβ) assembly by homologous C-terminal fragments as a strategy for inhibiting Aβ toxicity[J]. ACS chemical neuroscience, 2016, 7(7): 845-856.
[2] Ghosh N, Kundu L M. Breaker peptides against amyloid-β aggregation: a potential therapeutic strategy for Alzheimer’s disease[J]. Future Medicinal Chemistry, 2021, 13(20): 1767-1794.
[3] Cheung N S, Small D H, Livett B G. An Amyloid Peptide, βA4 25–35, Mimics the Function of Substance P on Modulation of Nicotine‐Evoked Secretion and Desensitization in Cultured Bovine Adrenal Chromaffin Cells[J]. Journal of neurochemistry, 1993, 60(3): 1163-1166.
[4] Aleksis R, Oleskovs F, Jaudzems K, et al. Structural studies of amyloid-β peptides: Unlocking the mechanism of aggregation and the associated toxicity[J]. Biochimie, 2017, 140: 176-192.
[5] Rahimi F, Li H, Sinha S, et al. Modulators of amyloid β-protein (Aβ) self-assembly[M]//Developing Therapeutics for Alzheimer's Disease. Academic Press, 2016: 97-191.
[6] Millucci L, Ghezzi L, Bernardini G, et al. Conformations and biological activities of amyloid beta peptide 25-35[J]. Current Protein and Peptide Science, 2010, 11(1): 54-67.
Amyloid β-Protein (25-35) amide是β淀粉样蛋白(amyloid-β,Aβ)酰胺化的一种产物,其中β淀粉样蛋白的生成能力已被强烈降低[1]。Amyloid β-Protein (25-35) amide是β淀粉样肽的修饰片段序列,由25-35位氨基酸组成,C端被酰胺键封闭[2]。Aβ (25-35) 肽的氨基酸序列为 NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH,其中第一个Gly代表氨基酸25,最后一个Met代表氨基酸35[3]。Aβ具有神经毒性,但毒性强弱与其聚集状态无关,Aβ寡聚体也表现出神经毒性并导致神经元损伤[4, 5]。Aβ参与阿尔茨海默病的发病机制,存在于阿尔茨海默氏症大脑样本和包涵体肌炎(IBM)肌肉的下托和内嗅皮层神经元中,它与小胶质细胞中存在的受体结合,并且能够插入脂质膜[6]。
Cas No. | 147490-49-1 | SDF | |
分子式 | C45H82N14O13S | 分子量 | 1059.3 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 0.944 mL | 4.7201 mL | 9.4402 mL |
5 mM | 0.1888 mL | 0.944 mL | 1.888 mL |
10 mM | 0.0944 mL | 0.472 mL | 0.944 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet